CY2166B1 - Freeze-dried composition containing ondansetron - Google Patents

Freeze-dried composition containing ondansetron

Info

Publication number
CY2166B1
CY2166B1 CY0000011A CY0000011A CY2166B1 CY 2166 B1 CY2166 B1 CY 2166B1 CY 0000011 A CY0000011 A CY 0000011A CY 0000011 A CY0000011 A CY 0000011A CY 2166 B1 CY2166 B1 CY 2166B1
Authority
CY
Cyprus
Prior art keywords
freeze
composition containing
dried composition
ondansetron
containing ondansetron
Prior art date
Application number
CY0000011A
Other languages
English (en)
Inventor
Ian Keith Winterborn
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2166(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of CY2166B1 publication Critical patent/CY2166B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Detergent Compositions (AREA)
  • Fertilizers (AREA)
CY0000011A 1994-11-22 2000-05-02 Freeze-dried composition containing ondansetron CY2166B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions

Publications (1)

Publication Number Publication Date
CY2166B1 true CY2166B1 (en) 2002-08-23

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0000011A CY2166B1 (en) 1994-11-22 2000-05-02 Freeze-dried composition containing ondansetron

Country Status (31)

Country Link
US (2) US5955488A (da)
EP (1) EP0793495B1 (da)
JP (1) JP3001264B2 (da)
KR (1) KR970706814A (da)
CN (1) CN1080118C (da)
AT (1) ATE193444T1 (da)
AU (1) AU704160B2 (da)
BE (1) BE1010250A3 (da)
BR (1) BR9509808A (da)
CY (1) CY2166B1 (da)
CZ (1) CZ285250B6 (da)
DE (1) DE69517332T2 (da)
DK (1) DK0793495T3 (da)
ES (1) ES2147309T3 (da)
FI (1) FI119355B (da)
FR (1) FR2727016B1 (da)
GB (2) GB9423511D0 (da)
GR (1) GR3033937T3 (da)
HK (1) HK1009591A1 (da)
HU (1) HU226891B1 (da)
IL (1) IL116084A (da)
IT (1) IT1282352B1 (da)
MX (1) MX9703735A (da)
NO (1) NO306893B1 (da)
NZ (1) NZ296982A (da)
PL (1) PL181179B1 (da)
PT (1) PT793495E (da)
RU (1) RU2159614C2 (da)
TW (1) TW398976B (da)
WO (1) WO1996015785A1 (da)
ZA (1) ZA959821B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
CZ20031397A3 (cs) * 2000-10-30 2003-11-12 Teva Pharmaceutical Industries Ltd. Nové krystalické a solvatované formy ondansetron hydrochloridu a způsoby jejich přípravy
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
US7098345B2 (en) * 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
EP1465887A1 (en) * 2002-04-30 2004-10-13 Teva Gyogyszergyar Reszvenytarsasag Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
JP2007508271A (ja) 2003-10-10 2007-04-05 シントン・ベスローテン・フェンノートシャップ 固体状態のモンテルカスト
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
CA2567720A1 (en) * 2004-05-24 2005-12-08 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR056815A1 (es) * 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
CN101432267A (zh) * 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
UA97653C2 (ru) * 2006-10-24 2012-03-12 Хелсинн Хелткер С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, которые имеют улучшенную стабильность и биологическую доступность
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
JP5955767B2 (ja) * 2009-05-20 2016-07-20 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬
EP2253316B1 (en) * 2009-05-20 2013-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
US11612605B2 (en) 2016-04-14 2023-03-28 Sensorion (+)-azasetron for use in the treatment of ear disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3275121D1 (en) * 1981-12-11 1987-02-19 Wyeth John & Brother Ltd Process for preparing solid shaped articles
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
DE69517332T2 (de) 2000-11-30
GB9523667D0 (en) 1996-01-24
CZ285250B6 (cs) 1999-06-16
US5955488A (en) 1999-09-21
PT793495E (pt) 2000-10-31
GR3033937T3 (en) 2000-11-30
GB2295318B (en) 1998-10-28
HU226891B1 (en) 2010-01-28
PL320295A1 (en) 1997-09-15
AU704160B2 (en) 1999-04-15
RU2159614C2 (ru) 2000-11-27
AU4173996A (en) 1996-06-17
CN1171741A (zh) 1998-01-28
HK1009591A1 (en) 1999-06-04
EP0793495B1 (en) 2000-05-31
JP3001264B2 (ja) 2000-01-24
FI972167A0 (fi) 1997-05-21
ATE193444T1 (de) 2000-06-15
NO972325L (no) 1997-05-22
FR2727016B1 (fr) 1998-04-03
CN1080118C (zh) 2002-03-06
IT1282352B1 (it) 1998-03-20
US6063802A (en) 2000-05-16
KR970706814A (ko) 1997-12-01
FI972167A (fi) 1997-05-21
IL116084A (en) 2000-01-31
ITRM950762A1 (it) 1997-05-20
ITRM950762A0 (da) 1995-11-20
BE1010250A3 (fr) 1998-04-07
WO1996015785A1 (en) 1996-05-30
CZ154997A3 (en) 1997-10-15
TW398976B (en) 2000-07-21
BR9509808A (pt) 1997-10-21
IL116084A0 (en) 1996-01-31
FR2727016A1 (fr) 1996-05-24
NZ296982A (en) 1998-06-26
ES2147309T3 (es) 2000-09-01
DK0793495T3 (da) 2000-10-09
NO972325D0 (no) 1997-05-21
DE69517332D1 (de) 2000-07-06
EP0793495A1 (en) 1997-09-10
GB2295318A (en) 1996-05-29
FI119355B (fi) 2008-10-31
HUT77886A (hu) 1998-09-28
JPH10508864A (ja) 1998-09-02
MX9703735A (es) 1998-07-31
ZA959821B (en) 1996-07-31
GB9423511D0 (en) 1995-01-11
NO306893B1 (no) 2000-01-10
PL181179B1 (pl) 2001-06-29

Similar Documents

Publication Publication Date Title
GB2295318B (en) Freeze-dried dosage form containing ondansetron
WO1996015786A3 (en) Oral compositions containing ondansetron
AP1637A (en) Celecoxib compositions.
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
CA2205600A1 (en) Freeze-dried ondansetron compositions